Annual Cash & Cash Equivalents
$6.76 M
+$3.82 M+130.17%
December 31, 2023
Summary
- As of February 7, 2025, TTNP annual cash & cash equivalents is $6.76 million, with the most recent change of +$3.82 million (+130.17%) on December 31, 2023.
- During the last 3 years, TTNP annual cash & cash equivalents has risen by +$1.35 million (+24.88%).
- TTNP annual cash & cash equivalents is now -85.46% below its all-time high of $46.50 million, reached on December 31, 1999.
Performance
TTNP Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$3.40 M
-$693.00 K-16.94%
September 30, 2024
Summary
- As of February 7, 2025, TTNP quarterly cash and cash equivalents is $3.40 million, with the most recent change of -$693.00 thousand (-16.94%) on September 30, 2024.
- Over the past year, TTNP quarterly cash and cash equivalents has dropped by -$3.36 million (-49.72%).
- TTNP quarterly cash and cash equivalents is now -92.69% below its all-time high of $46.50 million, reached on December 31, 1999.
Performance
TTNP Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
TTNP Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +130.2% | -49.7% |
| 3 y3 years | +24.9% | -58.2% |
| 5 y5 years | -27.3% | -70.8% |
TTNP Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +130.2% | -58.2% | +3137.1% |
| 5 y | 5-year | at high | +130.2% | -70.8% | +3137.1% |
| alltime | all time | -85.5% | +651.1% | -92.7% | +3299.0% |
Titan Pharmaceuticals Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $3.40 M(-16.9%) |
| Jun 2024 | - | $4.09 M(-33.6%) |
| Mar 2024 | - | $6.16 M(-8.9%) |
| Dec 2023 | $6.76 M(+130.2%) | $6.76 M(-16.5%) |
| Sep 2023 | - | $8.10 M(+7610.5%) |
| Jun 2023 | - | $105.00 K(-90.8%) |
| Mar 2023 | - | $1.14 M(-61.3%) |
| Dec 2022 | $2.94 M(-51.4%) | $2.94 M(-34.0%) |
| Sep 2022 | - | $4.45 M(-30.7%) |
| Jun 2022 | - | $6.42 M(-21.1%) |
| Mar 2022 | - | $8.14 M(+34.8%) |
| Dec 2021 | $6.04 M(+11.5%) | $6.04 M(-18.6%) |
| Sep 2021 | - | $7.42 M(-23.4%) |
| Jun 2021 | - | $9.68 M(-16.8%) |
| Mar 2021 | - | $11.63 M(+114.8%) |
| Dec 2020 | $5.41 M(+3.6%) | $5.41 M(+32.9%) |
| Sep 2020 | - | $4.07 M(-25.9%) |
| Jun 2020 | - | $5.50 M(-31.6%) |
| Mar 2020 | - | $8.04 M(+53.9%) |
| Dec 2019 | $5.22 M(-43.8%) | $5.22 M(+467.1%) |
| Sep 2019 | - | $921.00 K(-59.8%) |
| Jun 2019 | - | $2.29 M(-61.2%) |
| Mar 2019 | - | $5.91 M(-36.4%) |
| Dec 2018 | $9.29 M(+23.6%) | $9.29 M(+10.3%) |
| Sep 2018 | - | $8.43 M(+422.1%) |
| Jun 2018 | - | $1.61 M(-53.4%) |
| Mar 2018 | - | $3.46 M(-53.9%) |
| Dec 2017 | $7.52 M(-46.3%) | $7.52 M(-35.6%) |
| Sep 2017 | - | $11.69 M(+40.0%) |
| Jun 2017 | - | $8.35 M(-23.2%) |
| Mar 2017 | - | $10.87 M(-22.4%) |
| Dec 2016 | $14.01 M(+78.3%) | $14.01 M(-15.1%) |
| Sep 2016 | - | $16.49 M(-14.6%) |
| Jun 2016 | - | $19.30 M(+235.0%) |
| Mar 2016 | - | $5.76 M(-26.7%) |
| Dec 2015 | $7.86 M(-49.2%) | $7.86 M(-18.9%) |
| Sep 2015 | - | $9.69 M(-15.7%) |
| Jun 2015 | - | $11.50 M(-14.3%) |
| Mar 2015 | - | $13.42 M(-13.2%) |
| Dec 2014 | $15.47 M(+31.1%) | $15.47 M(+107.7%) |
| Sep 2014 | - | $7.45 M(-15.8%) |
| Jun 2014 | - | $8.85 M(-13.5%) |
| Mar 2014 | - | $10.24 M(-13.2%) |
| Dec 2013 | $11.80 M(-34.8%) | $11.80 M(+31.1%) |
| Sep 2013 | - | $9.00 M(-19.5%) |
| Jun 2013 | - | $11.18 M(-36.5%) |
| Mar 2013 | - | $17.61 M(-2.7%) |
| Dec 2012 | $18.10 M(+234.9%) | $18.10 M(+257.6%) |
| Sep 2012 | - | $5.06 M(+23.3%) |
| Jun 2012 | - | $4.10 M(+77.8%) |
| Mar 2012 | - | $2.31 M(-57.3%) |
| Dec 2011 | $5.41 M(+70.0%) | $5.41 M(+95.0%) |
| Sep 2011 | - | $2.77 M(-54.5%) |
| Jun 2011 | - | $6.09 M(+661.5%) |
| Mar 2011 | - | $800.00 K(-74.8%) |
| Dec 2010 | $3.18 M | $3.18 M(-50.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2010 | - | $6.40 M(+340.8%) |
| Jun 2010 | - | $1.45 M(-11.6%) |
| Mar 2010 | - | $1.64 M(-50.2%) |
| Dec 2009 | $3.30 M(-87.1%) | $3.30 M(-73.0%) |
| Sep 2008 | - | $12.20 M(-32.8%) |
| Jun 2008 | - | $18.17 M(-25.3%) |
| Mar 2008 | - | $24.34 M(-5.0%) |
| Dec 2007 | $25.61 M(+166.5%) | $25.61 M(+2868.0%) |
| Sep 2007 | - | $863.00 K(-71.2%) |
| Jun 2007 | - | $3.00 M(+62.5%) |
| Mar 2007 | - | $1.85 M(-80.8%) |
| Dec 2006 | $9.61 M(+5.2%) | $9.61 M(+5.6%) |
| Sep 2006 | - | $9.10 M(+23.1%) |
| Jun 2006 | - | $7.39 M(-51.6%) |
| Mar 2006 | - | $15.28 M(+67.2%) |
| Dec 2005 | $9.14 M(+67.3%) | $9.14 M(+33.9%) |
| Sep 2005 | - | $6.83 M(+29.6%) |
| Jun 2005 | - | $5.27 M(-14.4%) |
| Mar 2005 | - | $6.16 M(+12.8%) |
| Dec 2004 | $5.46 M(-20.0%) | $5.46 M(-8.3%) |
| Sep 2004 | - | $5.96 M(+14.0%) |
| Jun 2004 | - | $5.22 M(-77.4%) |
| Mar 2004 | - | $23.08 M(+237.8%) |
| Dec 2003 | $6.83 M(-4.5%) | $6.83 M(-8.6%) |
| Sep 2003 | - | $7.47 M(-59.7%) |
| Jun 2003 | - | $18.54 M(+120.0%) |
| Mar 2003 | - | $8.43 M(+17.8%) |
| Dec 2002 | $7.16 M(+24.0%) | $7.16 M(+1.7%) |
| Sep 2002 | - | $7.04 M(+11.7%) |
| Jun 2002 | - | $6.30 M(+36.9%) |
| Mar 2002 | - | $4.60 M(-20.3%) |
| Dec 2001 | $5.77 M(-71.6%) | $5.77 M(-7.4%) |
| Sep 2001 | - | $6.23 M(-44.9%) |
| Jun 2001 | - | $11.32 M(+15.8%) |
| Mar 2001 | - | $9.77 M(-51.9%) |
| Dec 2000 | $20.30 M(-56.3%) | $20.30 M(+220.5%) |
| Sep 2000 | - | $6.33 M(+0.9%) |
| Jun 2000 | - | $6.28 M(+0.8%) |
| Mar 2000 | - | $6.23 M(-86.6%) |
| Dec 1999 | $46.50 M(+297.4%) | $46.50 M(+411.0%) |
| Sep 1999 | - | $9.10 M(-22.9%) |
| Jun 1999 | - | $11.80 M(-20.3%) |
| Mar 1999 | - | $14.80 M(+26.5%) |
| Dec 1998 | $11.70 M(-52.0%) | $11.70 M(-17.0%) |
| Sep 1998 | - | $14.10 M(-16.1%) |
| Jun 1998 | - | $16.80 M(-12.0%) |
| Mar 1998 | - | $19.10 M(-21.7%) |
| Dec 1997 | $24.40 M(+1642.9%) | $24.40 M(+343.6%) |
| Sep 1997 | - | $5.50 M(-51.8%) |
| Jun 1997 | - | $11.40 M(+235.3%) |
| Mar 1997 | - | $3.40 M(+142.9%) |
| Dec 1996 | $1.40 M(+55.6%) | $1.40 M(+180.0%) |
| Sep 1996 | - | $500.00 K(+400.0%) |
| Jun 1996 | - | $100.00 K(-66.7%) |
| Mar 1996 | - | $300.00 K(-66.7%) |
| Dec 1995 | $900.00 K | $900.00 K |
FAQ
- What is Titan Pharmaceuticals annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Titan Pharmaceuticals?
- What is Titan Pharmaceuticals annual cash & cash equivalents year-on-year change?
- What is Titan Pharmaceuticals quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Titan Pharmaceuticals?
- What is Titan Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
What is Titan Pharmaceuticals annual cash & cash equivalents?
The current annual cash & cash equivalents of TTNP is $6.76 M
What is the all time high annual cash & cash equivalents for Titan Pharmaceuticals?
Titan Pharmaceuticals all-time high annual cash & cash equivalents is $46.50 M
What is Titan Pharmaceuticals annual cash & cash equivalents year-on-year change?
Over the past year, TTNP annual cash & cash equivalents has changed by +$3.82 M (+130.17%)
What is Titan Pharmaceuticals quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of TTNP is $3.40 M
What is the all time high quarterly cash and cash equivalents for Titan Pharmaceuticals?
Titan Pharmaceuticals all-time high quarterly cash and cash equivalents is $46.50 M
What is Titan Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
Over the past year, TTNP quarterly cash and cash equivalents has changed by -$3.36 M (-49.72%)